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Acute Myocardial Infarction Masquerading as Infusion Reaction Following First
Sipuleucel-T Infusion for Castration Resistant Prostate Cancer
Zaid Al-Saheli MBBS, Nino Balanchivadze MD, Rawan Hammoudeh MBBS, Hanan Ibrahim MD, Clara Hwang MD
Henry Ford Health System, Detroit, Michigan

Introduction

Furthermore

Discussion

• Advances in cancer therapy have improved patient survival statistics;
however, treatment related adverse events can lead to significant morbidity
and may be life-threatening. Sipuleucel-T is the first FDA approved
therapeutic cancer vaccine which showed improved overall survival in
patients with metastatic castration resistant prostate cancer.

• The patient had no know previous history of coronary artery disease,
despite having a recent pharmacologic stress test, within the prior year,
which did not reveal any inducible ischemia, and a coronary CT scan
without evidence of obstructive disease. Transthoracic echocardiogram 2
months prior to presentation revealed normal ejection fraction of 60%
without any wall motion abnormalities.

• Prostate cancer is the most common non-cutaneous malignancy, and a leading cause of
cancer mortality amongst men in the Western world. Castration resistant prostate cancer
occurs when disease progresses despite castrate levels of androgens.
• Historically, the prognosis of CRPC has been guarded with survival estimates of 18 to 24
months.

• We describe a case of acute ST-segment elevation myocardial infarction
(STEMI) in a patient during the first Sipuleucel-T infusion. Our aim is to
increase physician awareness of this potential complication in order to
avoid catastrophic outcomes.

• This acute STEMI was therefore attributed to the Sipuleucel-T
infusion. Further treatments with Sipuleucel-T were subsequently
deferred by the primary oncologist.

Case Presentation
• A 59 year old African American male with metastatic castrate resistant
prostate cancer, hypertension, type II diabetes mellitus, was receiving his
first Sipuleucel-T infusion at an outpatient infusionn center when he
developed sudden chills.
• No signs or symptoms of anaphylaxis were reported, however, the
patient’s presentation was attributed to an infusion reaction, which
resolved after administration of 50mg of diphenhydramine.
• Within 20 minutes, he developed substernal chest tightness radiating to
his left arm, along with dyspnea and diaphoresis. Vital signs were notable
for BP 90/40, HR 94, and oxygen saturation 96% on room air. Physical
exam revealed a diaphoretic male, with normal cardiac, chest, abdominal
and extremity examination.
• He was given aspirin 81 mg, and sublingual nitroglycerin. EKG was
obtained which showed ST-segment elevation in leads III, AVF with
reciprocal depressions in the anterolateral leads (Figure 1).

Figures
Figure 1: EKG revealing ST-segment elevation in leads III, AVF with reciprocal
depressions in the anterolateral leads

• Sipuleucel-T, a type of therapeutic cancer vaccine, is thought to work through antigen
presenting cells to stimulate T-cell immune response targeted against prostatic acid
phosphatase, an antigen that is highly expressed in most prostate cancer cells.
• Based on phase 3 randomized trial evidence, Sipuleucel-T is a category 1 recommended
option for patients with metastatic CRPC who are asymptomatic or minimally
symptomatic, and have good performance levels.
• Although almost a decade has passed since its approval, there remains a paucity of
literature describing safety data in the post-marketing period. The most common adverse
events among patients treated with Sipuleucel-T were chills, fatigue, fever, back pain,
nausea, arthralgia, and headache.
• A recent descriptive analysis of FAERS database identified 38 reports (all serious) of
acute myocardial infarction. Cardiac risk factors (hypertension, diabetes, coronary artery
disease, or hyperlipidemia) were specified in 68% of reports. Most events occurred after
the second (n = 14) or third (n = 11) dose of Sipuleucel-T; 6 events occurred after the first
dose, and 5 reports did not specify the timing of subsequent MI. Most MIs occurred
within 1 week of a Sipuleucel-T infusion (19 [53%], with 12 of these reports describing
MI on the same day as an infusion) or 8 to 30 days after an infusion (n = 11).
• The mechanism of development of acute STEMI with Sipuleucel-T infusion is unclear,
but could be related to activation of T cells and cytokines along with other mediator
release leading to inflammation and possibly coronary vasospasm and/or thrombus
formation.

Figure 2: Initial angiogram in the setting of inferior STEMI showing occlusion of midRCA (A), and post-primary PCI intervention angiogram (B) showing restoration of
flow down entire RCA

Conclusion
• Sipuleucel-T is a category I recommended option for patients with metastatic
CRPC. Infusion related adverse events are common, of which serious cardiac
events, including myocardial infarction, have been noted with its infusion,
particularly in patients with cardiac risk factors.
•

• Emergent coronary angiogram revealed a mid-RCA culprit lesion with
99% obstruction with TIMI I flow (Figure 2) for which a Synergy drugeluting stent (DES) was placed.
• During post-procedural recovery, the patient developed recurrent chest
pain with repeat EKG showing worsened inferior STEMI.
• Repeat emergent angiogram revealed acute in-stent thrombosis and
likely plaque protrusion in the proximal edge of the recently placed stent
with distal thrombus embolization (Figure 3).
• The lesion was treated with balloon angioplasty, additional DES
placement proximally, administration of eptifibatide and placement of an
intra-aortic balloon pump to improve coronary perfusion.
• He improved quickly, and was discharged home in satisfactory
condition with appropriate goal directed therapy.

Figure 3: Repeat emergent angiogram showing acute in-stent thrombosis (A), as marked
by the arrow, with likely distal thrombus embolization, and post-repeat intervention (B)
showing restoration of flow down RCA.

To our knowledge, this is the first case report describing STEMI in a patient
during the first Sipuleucel-T infusion. Increased awareness of this potential
adverse event is important for involved physicians, not only for prompt diagnosis
to avoid significant morbidity and mortality of affected patients, but in order to
help risk-stratify which patients would be considered appropriate candidates for
such therapy.
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